Clinical Trial Details
— Status: Recruiting
Administrative data
NCT number |
NCT05210842 |
Other study ID # |
HA Salzburg |
Secondary ID |
|
Status |
Recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
February 2022 |
Est. completion date |
February 2022 |
Study information
Verified date |
January 2022 |
Source |
Salzburger Landeskliniken |
Contact |
Antonia Gantschnigg, Dr. |
Phone |
06607154088 |
Email |
a.gantschnigg[@]salk.at |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Lumen approximating stents have been used in interventional endoscopy to treat retentions in
the upper gastrointestinal tract for 10 years. In the last few years, these have also been
used with great success to form new anastomoses, especially in palliative patients. In this
regard, many studies have been conducted in recent years.
As one of the largest centers for interventional endoscopy in Austria, we have been
performing such interventions as standard since 2016.
The use of LAMS has become the standard therapy in many places. Most of the literature
describes the technical advantages of LAMS, while the complications are less discussed.
Although complications are rare with reported rates below 10%, with the multitude of
technological and clinical advances in the field, it is important to understand and manage
potential complications such as bleeding, perforation and stent migration.
Our goal is to evaluate the safety, efficacy, and outcome of all EC-LAMS in a single,
high-volume center.
Method:
Suitable patients are analyzed retrospectively from the existing database. All patients who
had a lumen-proximating stent implanted are included.
Description:
Electrocautery-enhanced lumen-apposing stents (EC-LAMS) were originally designed for drainage
of the gallbladder, bile duct, and pancreas pseudocysts.
Numerous studies have shown the effectiveness in treating pseudocysts, abscesses and
walled-off pancreatic necrosis by creating a cystogastrostomy or cystoenterostomy tract with
a LAMS for drainage and necrosectomy.
In patients suffering from acute cholecystitis, unfit for surgery due to significant
comorbidities and/or essential need of anticoagulation, percutaneous gallbladder drainage
(PTGBD) was considered as the viable treatment option. However, this procedure comes along
with a high incidence of complications like bile leak, bowel perforation, catheter
displacement, and cholangitis. Several studies compared the outcome of PTGBD with the
endoscopic ultrasound-guided gallbladder drainage (EUS-GBD). The results show significantly
superior results in the treatment of non-surgical acute cholecystitis patients with EUS-GBD,
in order to consider the use of EUS-GBD as the treatment of choice.
Further, newer "off-label indications" of LAMS are to drain the bile duct in case of failed
ERCP (endoscopic retrograde cholangiopancreatography) or, in patients where an ERCP is not
possible due to malignant distal biliary obstructions, duodenal obstruction, or post-surgery
anatomy. The creation of gastro-gastrostomy was used in patients with a gastric bypass to
enable to perform an ERCP or drain a postoperative abscess/fluid collection. Results of
published studies have already shown satisfactory clinical outcomes in stenting benign
structures, mainly strictures near gastrointestinal (GI) anastomoses or due to chronic
inflammations (gastroesophageal junction, pylorus).
We aim to evaluate the safety, efficacy, and outcome of all EC-LAMS placed in a single
high-volume center.